1Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtu- zumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood, 2012, 119 : 345-354.
2Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006, 108:2509-2519.
4Dufour C, Ferretti E, Bagnasco F, et al. Changes in cytokine pro- file pre- and post-immunosuppression in acquired aplastic anemia. Haematological, 2009, 94 : 1743-1747.
5Omokaro SO, Desierto M J, Eckhaus MA, et al. Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model. J Immunol, 2009, 182:3414- 3422.
6Tanaka Y, Altman A. T cell signaling: Protein kinase C O, the immunological synapse and characterization of SLAT, a novel T helper2-specific adapter protein. Allergology Int, 2002, 51:167- 174.
7Marsland B J, Kopf M. T-cell fate and function : PKC-theta and be- yond. Trends Immunol, 2008, 29: 179-185.
8Zanin-Zhorov A, Dustin ML, Blazar BR. PKC-0 function at the immunological synapse:prospects for therapeutic targeting. Trend in immunology, 2011, 32:358-363.
9Kaito K, Otsubo H, Usul N, et al. Thl/Th2 lymphocyte balance in patients with aplastic anemia. Rinsho Byori, 2004, 52:569- 573.
10Zeng W, Kajigaya S, Chen G, et al. Transcript profile of CIM + and CD8 + T cells from the bone marrow of acquired aplastic ane- mia patients. Exp Hematol, 2004, 32:806-814.
